Расширенный поиск

Таргетная терапия распространенного рака почки

Полный текст:

Об авторах

Б. Я. Алексеев
МНИОИ им. П.А. Герцена

П. В. Шегай
МНИОИ им. П.А. Герцена

Список литературы

1. Godley P.A., Taylor M. Renal cell carcinoma. Curr Opin Oncol 2001;13:199—203.

2. Jemal A., Tiwari R.C., Murray T. et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54(1):8—29.

3. Чиссов В.И., Старинский В.В., Петрова Г.В. (ред.) Злокачественные новообразования в России в 2005 году. М.; 2007.

4. Janzen N.K., Kim H.L., Figlin R.A., Belldegrun A.S. Surveilance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003;30(4):843—52.

5. Motzer R.J., Bacik J., Murphy B.A. et al. Interferon-alpha as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289—96.

6. Motzer R.J., Bacik J., Schwartz L.H. et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22(3):454—63.

7. Motzer R.J., Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000;163:408—17.

8. Fojo A.T., Shen D.W., Mickley L.A. et al. Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene. J Clin Oncol 1987;5:1922—7.

9. Ernest S., Rajaraman S., Megyesi J. et al. Expression of MDR1 (multidrug resistance) gene and its protein in normal human kidney. Nephron 1997;77:284—9.

10. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomized controlled trial. Lancet 1999;353:14—7.

11. Huland E., Heinzer H.Survival in renal cell carcinoma: a randomized evaluation of tamoxifen vs interleukin-2, alpha-interferon (leucocyte) and tamoxifen. Br J Cancer 2000;82:246—7.

12. Atzpodien J., Kirchner H., Illiger H.J. et al. IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 2001;85:1130—6.

13. Vogelzang N.J., Priest E.R., Borden L. Spontaneous regression of hystologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year follow-up. J Urol 1992;148:1247—8.

14. Oliver R.T.D., Mehta A., Barnett M.J. A phase 2 study of surveillance in patients with metastatic renal cell and assessment of response of such patients to therapy on progression. Mol Biother 1998;1:14—20.

15. McDermott D.F., Regan M.M., Clark J.L. et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133—41.

16. Yang J.C., Sherry R.M., Steinberg S.M. et al. Randomized study of high-dose and lowdose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:3127—32.

17. Coppin C., Porzsolt F., Awa A. et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005; CD001425.

18. Bergers G., Song S., Meyer-Morse N. et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111(9): 1287—95.

19. Maxwell P.H., Wiesener M.S., Chang G.W. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygendependent proteolysis. Nature 1999;399:271—5.

20. Kaelin W.G. Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002;2(9):673—82.

21. Rini B.I., Small E.J. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005;23:1028—13.

22. de Paulsen N., Brychzy A., Foumier M.C. et al. Role of transforming growth factoralpha in von Hippel-Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci USA 2001;98:1387—92.

23. Gollob J.A., Wilhelm S., Carter C. et al. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ ERK signal transduction pathway. Semin Oncol 2006;33:392—406.

24. Schwartz G., Dutcher J.P., Vogelzang N.J. et al. Phase 2 clinical trial evaluating the safety and effectiveness of ABX-EGF in renal cell cancer. Proc Am Soc Clin Oncol 2002;21:24a (abstr 91).

25. Ravaud A., Gardner J., Hawkins R. et al. Efficacy of lapatinib in patients with high tumor EGFR expression: results of a phase III trial in advanced renal cell carcinoma (RCC). J Clin Oncol 2006;24(Suppl.):217s (abstr 4502).

26. Hudes G., Carducci M., Tomczac P. et al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). J Clin Oncol 2006; 24(Suppl):2S (abstr LBA4).

27. Motzer R.J., Amato R., Todd M. et al. Phase II trial of anti-epidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 2003;21:99—101.

28. Ratain M.J., Eisen T., Stadler W.M. et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505—12.

29. Yang J.C., Haworth L., Sherry R.M. et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427—34.

30. Hurwitz H., Dowlati A., Savage S. et al. Safety, tolerability and pharmacokinetics of oral administration of GW786034 in patients with solid tumors. J Clin Oncol 2005;23(Suppl 16S):195s (abstr 3012).

31. Motzer R.J., Michaelson M.D., Redman B.G. et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16—24.

32. Motzer R.J., Rini B.I., Bukowski R.M. et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516—24.

33. Motzer R.J., Hutson T.E. Tomczac P. et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-a) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2006;24(Suppl):2S (abstr LBA3).

34. Amato R.J., Misellati A., Khan M. et al. A phase II trial of RAD001 in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2006;24(Suppl.):224S (abstr 4530).

35. Wilhelm S., Carter C., Tang L. et al. BAY 43-9006 exhibits broad spectrum anti-tumor activity and targets raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Clin Cancer Res 2004;64:7099—109.

36. Awada A., Hendlisz A., Gil T. et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92(10):1855—61.

37. Strumberg D., Richly H., Hilger R.A. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23(5):965—72.

38. Escudier B., Szczylik C., Demkow T. et al. Randomized phase II trial of the multi-kinase inhibitor sorafenib versus interferon (IFN) in treatment naive patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2006;24(Suppl):18S (abstr 4501).

39. Escudier B., Eisen T., Stadler W. et al. Sorafenib in advanced clear-cell renal carcinoma. N Engl J Med 2007;356:125—34.

40. Elsen T., Bukowski R.M., Staehler M. et al. Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): impact of crossover on survival. J Clin Oncol 2006; 24 (Suppl):223S (abstr 4524).

41. Motzer R.J., Hutson T.E., Tomczak P. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115—24.


Для цитирования:

Алексеев Б.Я., Шегай П.В. Таргетная терапия распространенного рака почки. Онкоурология. 2007;3(4):6-11.

For citation:

Alekseyev B.Y., Shegai P.V. Target therapy for disseminated renal cancer. Cancer Urology. 2007;3(4):6-11. (In Russ.)

Просмотров: 192

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)